• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 mRNA 和 miRNA 表达数据的荟萃分析鉴定多发性骨髓瘤中的潜在生物标志物。

Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data.

机构信息

Bioinformatics Facility, Centralized Core Research Facility, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.

ICMR-AIIMS Computational Genomics Centre, Division of Biomedical Informatics, Indian Council of Medical Research, Ansari Nagar, New Delhi, 110029, India.

出版信息

Sci Rep. 2021 May 26;11(1):10957. doi: 10.1038/s41598-021-90424-y.

DOI:10.1038/s41598-021-90424-y
PMID:34040057
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8154993/
Abstract

Multiple myeloma (MM) is a plasma cell malignancy with diverse clinical phenotypes and molecular heterogeneity not completely understood. Differentially expressed genes (DEGs) and miRNAs (DEMs) in MM may influence disease pathogenesis, clinical presentation / drug sensitivities. But these signatures overlap meagrely plausibly due to complexity of myeloma genome, diversity in primary cells studied, molecular technologies/ analytical tools utilized. This warrants further investigations since DEGs/DEMs can impact clinical outcomes and guide personalized therapy. We have conducted genome-wide meta-analysis of DEGs/DEMs in MM versus Normal Plasma Cells (NPCs) and derived unified putative signatures for MM. 100 DEMs and 1,362 DEGs were found deranged between MM and NPCs. Signatures of 37 DEMs ('Union 37') and 154 DEGs ('Union 154') were deduced that shared 17 DEMs and 22 DEGs with published prognostic signatures, respectively. Two miRs (miR-16-2-3p, 30d-2-3p) correlated with survival outcomes. PPI analysis identified 5 topmost functionally connected hub genes (UBC, ITGA4, HSP90AB1, VCAM1, VCP). Transcription factor regulatory networks were determined for five seed DEGs with ≥ 4 biomarker applications (CDKN1A, CDKN2A, MMP9, IGF1, MKI67) and three topmost up/ down regulated DEMs (miR-23b, 195, let7b/ miR-20a, 155, 92a). Further studies are warranted to establish and translate prognostic potential of these signatures for MM.

摘要

多发性骨髓瘤(MM)是一种浆细胞恶性肿瘤,其临床表现和分子异质性多种多样,尚未完全了解。MM 中的差异表达基因(DEGs)和 microRNAs(DEMs)可能影响疾病发病机制、临床表现/药物敏感性。但是,由于骨髓瘤基因组的复杂性、研究的原代细胞多样性、所使用的分子技术/分析工具的多样性,这些特征重叠甚少。这需要进一步的研究,因为 DEGs/DEMs 可以影响临床结果并指导个性化治疗。我们对 MM 与正常浆细胞(NPCs)中的 DEGs/DEMs 进行了全基因组荟萃分析,并得出了 MM 的统一假定特征。在 MM 和 NPCs 之间发现了 100 个 DEMs 和 1362 个 DEGs 失调。推断出 37 个 DEMs(“Union 37”)和 154 个 DEGs(“Union 154”)的特征,分别与已发表的预后特征共享 17 个 DEMs 和 22 个 DEGs。两个 miR(miR-16-2-3p,30d-2-3p)与生存结果相关。PPI 分析确定了 5 个功能连接度最高的 hub 基因(UBC、ITGA4、HSP90AB1、VCAM1、VCP)。确定了五个具有≥4 种生物标志物应用(CDKN1A、CDKN2A、MMP9、IGF1、MKI67)和三个上调/下调最明显的 DEMs(miR-23b、195、let7b/miR-20a、155、92a)的种子 DEGs 的转录因子调控网络。需要进一步的研究来确定和转化这些 MM 特征的预后潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/2d754288ef06/41598_2021_90424_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/b35165b80f3f/41598_2021_90424_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/a33c908d48d1/41598_2021_90424_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/39734108d9ce/41598_2021_90424_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/0092fe2643bc/41598_2021_90424_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/2d754288ef06/41598_2021_90424_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/b35165b80f3f/41598_2021_90424_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/a33c908d48d1/41598_2021_90424_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/39734108d9ce/41598_2021_90424_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/0092fe2643bc/41598_2021_90424_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/232d/8154993/2d754288ef06/41598_2021_90424_Fig5_HTML.jpg

相似文献

1
Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data.基于 mRNA 和 miRNA 表达数据的荟萃分析鉴定多发性骨髓瘤中的潜在生物标志物。
Sci Rep. 2021 May 26;11(1):10957. doi: 10.1038/s41598-021-90424-y.
2
Microarray profile analysis identifies ETS1 as potential biomarker regulated by miR-23b and modulates TCF4 in gastric cancer.微阵列分析鉴定出 ETS1 是受 miR-23b 调控的潜在生物标志物,并调节胃癌中的 TCF4。
World J Surg Oncol. 2021 Oct 23;19(1):311. doi: 10.1186/s12957-021-02417-w.
3
Identification of crucial miRNAs and genes in esophageal squamous cell carcinoma by miRNA-mRNA integrated analysis.通过miRNA-mRNA整合分析鉴定食管鳞状细胞癌中的关键miRNA和基因
Medicine (Baltimore). 2019 Jul;98(27):e16269. doi: 10.1097/MD.0000000000016269.
4
Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.利用生物信息学分析非小细胞肺癌患者血浆中潜在的 miRNA-mRNA 调控网络。
BMC Cancer. 2022 Mar 21;22(1):299. doi: 10.1186/s12885-022-09281-1.
5
Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma.生物信息学分析鉴定出雌激素受体 1 (ESR1) 基因和 hsa-miR-26a-5p 是肝内胆管癌患者的潜在预后生物标志物。
Med Sci Monit. 2020 May 21;26:e921815. doi: 10.12659/MSM.921815.
6
Construction of an miRNA-mRNA regulatory network in colorectal cancer with bioinformatics methods.基于生物信息学方法构建结直肠癌 miRNA-mRNA 调控网络。
Anticancer Drugs. 2019 Jul;30(6):588-595. doi: 10.1097/CAD.0000000000000745.
7
Identification of an MiRNA-mRNA Regulatory Network in Colorectal Cancer.结直肠癌中一个微小RNA-信使核糖核酸调控网络的鉴定
Comb Chem High Throughput Screen. 2021;24(10):1736-1745. doi: 10.2174/1386207323666201110154142.
8
Bone marrow stromal cells derived exosomal miR-10a and miR-16 may be involved in progression of patients with multiple myeloma by regulating EPHA8 or IGF1R/CCND1.骨髓基质细胞衍生的外泌体 miR-10a 和 miR-16 可能通过调节 EphA8 或 IGF1R/CCND1 参与多发性骨髓瘤患者的进展。
Medicine (Baltimore). 2021 Jan 29;100(4):e23447. doi: 10.1097/MD.0000000000023447.
9
Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.通过生物信息学分析整合多个GEO数据集鉴定多发性骨髓瘤中的关键基因并构建微小RNA-信使核糖核酸调控网络
Int J Hematol. 2017 Jul;106(1):99-107. doi: 10.1007/s12185-017-2216-2. Epub 2017 Mar 18.
10
Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.通过生物信息学分析鉴定骨髓瘤侧群细胞中的关键基因和通路。
Int J Med Sci. 2020 Jul 25;17(14):2063-2076. doi: 10.7150/ijms.48244. eCollection 2020.

引用本文的文献

1
Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens.对骨髓CD138+细胞进行蛋白质组学分析,以鉴定与多发性骨髓瘤患者对常用治疗方案反应相关的蛋白质。
Proteomics. 2025 Aug;25(16):48-60. doi: 10.1002/pmic.70025. Epub 2025 Aug 7.
2
Detection of early relapse in multiple myeloma patients.多发性骨髓瘤患者早期复发的检测
Cell Div. 2025 Jan 29;20(1):4. doi: 10.1186/s13008-025-00143-3.
3
Interference with PLA2G16 promotes cell cycle arrest and apoptosis and inhibits the reprogramming of glucose metabolism in multiple myeloma cells by modulating the Hippo/YAP signaling pathway.

本文引用的文献

1
Roles of miRNA dysregulation in the pathogenesis of multiple myeloma.miRNA 失调在多发性骨髓瘤发病机制中的作用。
Cancer Gene Ther. 2021 Dec;28(12):1256-1268. doi: 10.1038/s41417-020-00291-4. Epub 2021 Jan 5.
2
Revealing the impact of structural variants in multiple myeloma.揭示多发性骨髓瘤中结构变异的影响。
Blood Cancer Discov. 2020 Nov;1(3):258-273. doi: 10.1158/2643-3230.BCD-20-0132. Epub 2020 Sep 15.
3
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients.
干扰 PLA2G16 通过调节 Hippo/YAP 信号通路促进多发性骨髓瘤细胞的细胞周期停滞和凋亡,并抑制葡萄糖代谢的重编程。
Anticancer Drugs. 2024 Nov 1;35(10):902-911. doi: 10.1097/CAD.0000000000001642. Epub 2024 Jul 22.
4
m C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characteristics in acute myeloid leukemia.mC 调节子介导的甲基化修饰模式及急性髓系白血病肿瘤微环境浸润特征。
Immun Inflamm Dis. 2024 Jan;12(1):e1150. doi: 10.1002/iid3.1150.
5
HSP90β promotes osteoclastogenesis by dual-activation of cholesterol synthesis and NF-κB signaling.HSP90β 通过双重激活胆固醇合成和 NF-κB 信号通路促进破骨细胞生成。
Cell Death Differ. 2023 Mar;30(3):673-686. doi: 10.1038/s41418-022-01071-3. Epub 2022 Oct 5.
6
MiRNA as a Potential Target for Multiple Myeloma Therapy-Current Knowledge and Perspectives.微小RNA作为多发性骨髓瘤治疗的潜在靶点——当前认知与展望
J Pers Med. 2022 Aug 31;12(9):1428. doi: 10.3390/jpm12091428.
7
The Sec61 translocon is a therapeutic vulnerability in multiple myeloma.Sec61 转运蛋白是多发性骨髓瘤的治疗靶点。
EMBO Mol Med. 2022 Mar 7;14(3):e14740. doi: 10.15252/emmm.202114740. Epub 2022 Jan 11.
8
Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies.多发性骨髓瘤细胞衍生的外泌体:对肿瘤发生、诊断、预后和治疗策略的影响。
Cells. 2021 Oct 24;10(11):2865. doi: 10.3390/cells10112865.
9
The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications.mRNA 在多发性骨髓瘤生物学中的意义及其临床意义。
Int J Mol Sci. 2021 Nov 8;22(21):12070. doi: 10.3390/ijms222112070.
10
S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.S100钙结合蛋白家族成员与多发性骨髓瘤患者的不良预后及蛋白酶体抑制反应相关。
Front Cell Dev Biol. 2021 Aug 16;9:723016. doi: 10.3389/fcell.2021.723016. eCollection 2021.
血清微小RNA表达特征在预测多发性骨髓瘤患者对硼替佐米为基础治疗的难治性中的价值
Cancers (Basel). 2020 Sep 9;12(9):2569. doi: 10.3390/cancers12092569.
4
A 5-Gene Stemness Score for Rapid Determination of Risk in Multiple Myeloma.用于快速确定多发性骨髓瘤风险的5基因干性评分
Onco Targets Ther. 2020 May 18;13:4339-4348. doi: 10.2147/OTT.S249895. eCollection 2020.
5
Long non-coding RNA Sox2 overlapping transcript (SOX2OT) promotes multiple myeloma progression via microRNA-143-3p/c-MET axis.长非编码 RNA Sox2 重叠转录物 (SOX2OT) 通过 microRNA-143-3p/c-MET 轴促进多发性骨髓瘤进展。
J Cell Mol Med. 2020 May;24(9):5185-5194. doi: 10.1111/jcmm.15171. Epub 2020 Mar 21.
6
Reconstructing the evolutionary history of multiple myeloma.重建多发性骨髓瘤的进化史。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101145. doi: 10.1016/j.beha.2020.101145. Epub 2020 Jan 11.
7
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.转录组分析揭示了原发性浆细胞白血病和多发性骨髓瘤之间的显著差异,即使它们具有相似的遗传背景。
Blood Cancer J. 2019 Nov 20;9(12):90. doi: 10.1038/s41408-019-0253-1.
8
The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma.微小RNA在多发性骨髓瘤发病机制中的作用与功能
Cancers (Basel). 2019 Nov 6;11(11):1738. doi: 10.3390/cancers11111738.
9
A predicted risk score based on the expression of 16 autophagy-related genes for multiple myeloma survival.基于16个自噬相关基因表达的多发性骨髓瘤生存预测风险评分。
Oncol Lett. 2019 Nov;18(5):5310-5324. doi: 10.3892/ol.2019.10881. Epub 2019 Sep 19.
10
A Network Analysis of Multiple Myeloma Related Gene Signatures.多发性骨髓瘤相关基因特征的网络分析
Cancers (Basel). 2019 Sep 27;11(10):1452. doi: 10.3390/cancers11101452.